game betting,line roulette,bodog sportsbook

The Pfizer logo   | Photo Credit: Reuters

Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.,betdaq

The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.,iceexchange

"The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines," said Kathrin Jansen, head of vaccine research and development at Pfizer.,betdaq

The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.,euro 2020 qualifiers

Our code of editorial values

This article is closed for comments.
Please Email the Editor

Printable version | Oct 17, 2021 3:21:04 PM | ,bovada app

Next Story